Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novyra Pharmachem Limited (formerly Bansisons Tea Industries Ltd), listed on BSE (Scrip Code: 519353), has filed its 39th Annual Report for FY 2025-2026 and the notice of its AGM scheduled for June 25, 2026 via video conferencing. A major special business item is a Scheme of Capital Reduction proposing to cancel 85.71% of paid-up equity capital (54,25,714 shares), reducing the share capital from Rs.6.33 crore (63,30,000 shares) to Rs.90.43 lakh (9,04,286 shares), subject to NCLT approval. The company has accumulated losses of Rs.5.71 crore, of which Rs.5.43 crore will be written off as part of this reduction, signaling a balance sheet cleanup. Director changes include the resignation of Mrs. Mamy Ghosh (Nov 2025) and appointment/regularization of Mr. Anilkumar Amreliya as Executive Director and proposed Managing Director (5-year term) at a salary of just Rs.11,000/month, indicating the company has inadequate or no profits.
Existing shareholders will see their holdings effectively reverse-split — losing about 85.71% of their shares with no cash compensation — as the company writes off accumulated losses and resets its capital base. The move reflects serious financial distress and is intended to give the company a leaner balance sheet for future fundraising, but it materially reduces share count and signals weak financial health.